Medicenna Therapeutics Corp T.MDNA

Alternate Symbol(s): MDNAF

Healthcare Biotechnology

Medicenna Therapeutics Corp. is a Canada-based clinical-stage immunotherapy company. The Company's principal business activity is the development and commercialization of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its long-acting IL-2 Superkine, MDNA11, is an IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity, thereby preferentially stimulating cancer-killing effector T cells and NK cells. The Company’s IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials including a Phase IIb trial for recurrent glioblastoma (GBM). The Company’s early-stage Bifunctional SuperKine ImmunoTherapies (BiSKITs) program Targeted Metalloprotease Activated SuperKine (T-MASK) programs are designed to enhance the ability of Superkines to treat immunologically cold tumors.

TSX:MDNA - Post by User

Medicenna Therapeutics Corp

<< Previous

Bullboard Posts

Next >>

Post by peterkleinon Jan 20, 2021 5:47am

144 Views

Post# 32331562

the pain will continue today

Ready for another day of pain and lossses? Yup, $25 million ATM open market shameless sales happening every day by company and geniuses mgmt team! down down down... beware before buying... stock will continue to go down... no catalysts in sight

<< Previous

Bullboard Posts

Next >>

The investment impact of the U.S. 25% tariff on Canadian imports